|
시장보고서
상품코드
2049219
다형성교모세포종 치료 시장 보고서 : 약제 종류별, 투여 경로별, 분자 종류별, 유통 채널별, 지역별(2026-2034년)Glioblastoma Multiforme Treatment Market Report by Drug Type, Route of Administration, Type of Molecule, Distribution Channel, and Region 2026-2034 |
||||||
세계의 다형성교모세포종 치료 시장 규모는 2025년에 24억 달러에 달했습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 6.13%를 기록하며 2034년까지 42억 달러에 달할 것으로 예측하고 있습니다.
다형성교모세포종(IV등급 성상세포종이라고도 함)은 뇌세포 내에서 빠르게 퍼져 주변 세포를 감염시킬 수 있는 악성도 IV등급의 뇌종양입니다. 급속한 세포 변성이 특징이며, 뇌에 큰 압력을 가하여 심한 두통과 발작을 유발합니다. 이 질환의 정확한 원인은 아직 밝혀지지 않았지만, 투르코 증후군과 같은 희귀 유전성 질환을 포함한 몇 가지 요인이 원인으로 추정되고 있습니다. 이는 가장 치사율이 높은 뇌종양 중 하나이며, 치료 저항성을 보이기 때문에 진단 후 환자의 생존기간이 매우 짧습니다. 현재 치료법으로는 수술적 절제, 화학요법, 방사선 요법 등이 있습니다.
전 세계 종양성 질환의 유병률 증가와 고령 인구의 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한, 교모세포종 줄기세포의 내성에 대항하는 첨단 치료법 개발도 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한, 암 및 관련 질환에 대한 분자 생명공학 및 유전자 치료 연구개발(R&D) 활동이 활발해지면서 다양한 생물학적 제제의 개발이 진행되고 있습니다. 이러한 약물은 기존 치료법에 따른 부작용을 줄이는 데 도움이 되며, 환자들 사이에서 더 널리 받아들여지고 있습니다. 또한, 각국 정부의 의료 인프라 개선 노력과 다양한 치료 옵션에 대한 인식이 높아짐에 따라 시장 전망은 더욱 밝아질 것으로 예상됩니다.
목차
제1장 서문
제2장 분석 범위와 방법
제3장 주요 요약
제4장 소개
제5장 세계의 다형성교모세포종 치료 시장
제6장 시장 구분 : 약제 종류별
제7장 시장 구분 : 투여 경로별
제8장 시장 구분 : 분자 종류별
제9장 시장 구분 : 유통 채널별
제10장 시장 구분 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KSM 26.06.09The global glioblastoma multiforme treatment market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.2 Billion by 2034, exhibiting a growth rate (CAGR) of 6.13% during 2026-2034.
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
KEY MARKET SEGMENTATION:
Breakup by Drug Type:
- Temozolomide
- Bevacizumab
- Carmustine
- Radiosensitizers
- Others
Breakup by Route of Administration:
- Oral
- Parenteral
Breakup by Type of Molecule:
- Small Molecule
- Biologics
Breakup by Distribution Channel:
- Hospitals
- Pharmacies
- Others
Breakup by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
COMPETITIVE LANDSCAPE:
The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals. IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.
Key Questions Answered in This Report
1. What was the size of the global glioblastoma multiforme treatment market in 2025?
2. What is the expected growth rate of the global glioblastoma multiforme treatment market during 2026-2034?
3. What are the key factors driving the global glioblastoma multiforme treatment market?
4. What has been the impact of COVID-19 on the global glioblastoma multiforme treatment market?
5. What is the breakup of the global glioblastoma multiforme treatment market based on the route of administration?
6. What is the breakup of the global glioblastoma multiforme treatment market based on the type of molecule?
7. What is the breakup of the global glioblastoma multiforme treatment market based on the distribution channel?
8. What are the key regions in the global glioblastoma multiforme treatment market?
9. Who are the key players/companies in the global glioblastoma multiforme treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Glioblastoma Multiforme Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Drug Type
- 5.5 Market Breakup by Route of Administration
- 5.6 Market Breakup by Type of Molecule
- 5.7 Market Breakup by Distribution Channel
- 5.8 Market Breakup by Region
- 5.9 Market Forecast
6 Market Breakup by Drug Type
- 6.1 Temozolomide
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Bevacizumab
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Carmustine
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Radiosensitizers
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Parenteral
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Type of Molecule
- 8.1 Small Molecule
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Biologics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Europe
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Asia Pacific
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 10.4 Middle East and Africa
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
- 10.5 Latin America
- 10.5.1 Market Trends
- 10.5.2 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Sun Pharmaceutical Industries
- 15.3.2 Celldex Therapeutics
- 15.3.3 Pfizer
- 15.3.4 F. Hoffmann La Roche
- 15.3.5 Bristol-Myers Squibb
- 15.3.6 Teva Pharmaceuticals
- 15.3.7 Exelixis
- 15.3.8 Angiochem
- 15.3.9 Arbor Pharmaceuticals
